Kidney International® Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy Zigakibart, a humanized monoclonal antibody targeting A Proliferation-Inducing Ligand (APRIL), was tested in healthy volunteers and patients with IgA nephropathy (IgAN) in a Phase 1/2 trial with 100-week follow-up. The treatment was well tolerated and led...
Understanding and managing rare kidney diseases can be challenging, even for experienced nephrologists. The ISN Rare Kidney Diseases Toolkit offers concise, expert-led guidance to support timely recognition and informed decision-making in complex cases. Explore the ISN Rare Kidney Diseases Toolkit Focused, accessible, and clinically relevant The toolkit features practical resources on a range of rare conditions, with...
The ISN has added two new webinars to its Rare Kidney Disease Toolkit, focusing on immunoglobulin A nephropathy (IgAN) and C3 glomerulopathy (C3G). These expert-led sessions offer valuable insights into diagnosing, managing, and treating these rare but challenging kidney diseases. Watch "Advancements in C3 Glomerulopathy (C3G)," featuring David Kavanagh (UK), Alison Ma (Hong Kong), and...
